Hormone Therapy and the Brain: What Does the Evidence Actually Show?

What hormone therapy is established to treat

Menopausal hormone therapy has strong randomized evidence for reducing moderate to severe vasomotor symptoms — hot flashes and night sweats — and for genitourinary symptoms of menopause, and it is used for bone protection in appropriately selected women. Systemic estrogen with a progestogen for women with a uterus, or estrogen alone after hysterectomy, are the standard frameworks. Non-hormonal prescription options also exist for vasomotor symptoms, which matters for women in whom hormone therapy is not appropriate.

Effects relevant to neurologic symptoms

Most neurologic benefit reported by women on therapy is plausibly indirect. If night sweats are waking you six times a night, reducing them improves sleep, and improved sleep improves attention, mood, pain threshold and headache frequency. That is a legitimate route to feeling more clear-headed. It is different from a claim that estrogen directly enhances cognition, which trials have not established.

Migraine considerations

Migraine frequently changes during perimenopause, and the effect of hormone therapy on migraine varies between women. Because attacks are triggered by hormonal fluctuation rather than by low levels, clinicians commonly favor steady delivery — for example transdermal estradiol — and continuous rather than cyclical regimens when migraine is prominent. Some women notice improvement, some notice worsening, and dose or route adjustment is a normal part of the process. Migraine is not, by itself, a contraindication to menopausal hormone therapy.

Vascular and stroke considerations

Oral estrogen has been associated with a small increase in the risk of venous thromboembolism and ischemic stroke, with absolute risk in healthy women under 60 being low. Transdermal estradiol appears to carry a lower venous thromboembolism risk than oral preparations, which is one reason it is often preferred when vascular considerations are in play. Migraine with aura is independently associated with a higher relative risk of ischemic stroke, and smoking, uncontrolled hypertension, diabetes and dyslipidemia compound risk. This is why blood pressure control and smoking cessation belong in the same conversation as the prescription itself.

Timing and individualized risk

Clinical guidance generally favors initiation in women under approximately 60 or within ten years of the final menstrual period, where the balance of benefit and risk for symptom treatment is most favorable. Personal history of breast cancer, prior stroke or venous thromboembolism, active liver disease, unexplained vaginal bleeding, and cardiovascular disease change that calculation. Women with premature or early menopause are usually considered separately, since therapy until the typical age of menopause is standard practice for them.

Symptom treatment versus dementia prevention

These are different claims with very different evidence. Symptom relief is established. Dementia prevention is not, and is not an approved indication. In the Women’s Health Initiative Memory Study, therapy initiated in older postmenopausal women was associated with increased dementia risk, while observational data on earlier initiation have been mixed. Anyone marketing hormone therapy as brain protection is going beyond the evidence. Anyone refusing to discuss hormone therapy for disabling symptoms because of that same evidence is also misreading it.

How to approach the decision

Decide with a clinician who knows your full history: symptom severity and impact, cardiovascular risk factors, migraine subtype, breast and clot history, bone health, and your own priorities. Ask what the therapy is expected to improve, over what timeframe, how it will be reviewed, and what the alternatives are — including non-hormonal prescription options and treating sleep, mood and migraine directly.